Alnylam's big Phase 3 win; LGBTQ+ leaders charting paths; Chevron overturned;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View Article#EAN24: Dianthus teases preclinical data for autoimmune drug as it starts...
Dianthus Therapeutics has unveiled in vitro results of its drug candidate in a pair of autoimmune disease models, supporting recent efforts to start mid-stage studies. The first dataset from the blood...
View ArticleEisai takes over development of ADC after Bristol Myers ends $650M collaboration
Due to Bristol Myers Squibb’s portfolio prioritization efforts, Eisai is taking back an antibody-drug conjugate that they originally teamed up on in 2021. Eisai will now develop and commercialize the...
View ArticleClik here to view.
Aerovate plans to lay off nearly all employees after trial failure
Aerovate Therapeutics plans to lay off nearly all its employees two weeks after its lead asset flunked a mid-stage trial. The company disclosed the workforce reduction on Friday evening in an SEC...
View ArticleClik here to view.
Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech
Eli Lilly is further delving into the radiopharmaceutical field with a $140 million upfront deal with Radionetics Oncology. The strategic pact with the San Diego biotech could turn into a $1 billion...
View ArticleTracon to seek ‘strategic’ options; Ovid to lay off 17 workers
Plus, news about Merck, Orion, Tonix, Freeflow and Y-mAbs Therapeutics: Tracon Pharmaceuticals seeks ‘strategic alternatives’ after PD-L1 fails Ph2 trial: In an 82-person sarcoma study, only four...
View ArticleUniQure sells Massachusetts manufacturing site to Genezen as it continues to...
UniQure is selling its only US manufacturing site to viral vector CDMO Genezen for $25 million, as the gene therapy biotech continues to trim operations. The Lexington, MA, site makes uniQure’s...
View ArticleCorrected: Boehringer Ingelheim, Gubra put a second candidate into the...
Boehringer Ingelheim is beginning an early-stage trial for a triple agonist candidate for obesity that it’s developing with Danish biotech Gubra. The drug, dubbed BI 3034701, will be tested in a...
View ArticleFDA says chemotherapy cisplatin is no longer in short supply
According to the FDA and a triumphant tweet from FDA Commissioner Robert Califf, the shortage of the cancer drug cisplatin that began in February of last year has been resolved. The supply issues for...
View ArticleTakeda to lay off more employees in Massachusetts
Takeda plans to let go another 220 staffers in Massachusetts, where it was the largest biopharma in 2023 with 6,290 workers. The workforce reduction impacts 189 employees in Cambridge and 31 in...
View ArticleCassava says two senior employees included in federal probes
Following years of accusations of scientific malfeasance, Alzheimer’s drug developer Cassava Sciences disclosed Monday that two of its senior employees are being investigated by the US Securities and...
View ArticleSeeking 'financial flexibility,' Esperion sells European royalty on...
Esperion has made another deal with a financial backer for an immediate cash haul in return for future revenue. Esperion received $304.7 million from the investor OMERS Life Sciences, the biotech...
View ArticleFTC investigates Teva over patents, doubling down on 'bogus' Orange Book...
The Federal Trade Commission has turned up the pressure in its patent probe, officially launching a civil investigation into a group of Teva’s drug patents that the agency claims are improperly listed...
View ArticleCartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises...
Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many biopharmas in recent...
View ArticleSamsung Bio pulls in $1.06B manufacturing deal with unnamed US pharma company
Samsung Biologics has signed a manufacturing contract worth 1.46 trillion won ($1.06 billion) with an unnamed “large” US pharmaceutical company, making this at least the fourth major contract the...
View Article#EASD24: Weight loss readouts from Novo Nordisk, Boehringer Ingelheim,...
Companies large and small are set to present data on their next-generation weight loss drug candidates at the European Association for the Study of Diabetes annual meeting in Madrid, Spain. The...
View ArticleJ&J and Legend say Carvykti improves survival in earlier-line multiple myeloma
In a late-stage study, Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three prior lines of therapy compared to...
View ArticleCheckpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection
Checkpoint Therapeutics is taking a second shot at approval for its anti-PD-L1 candidate after the FDA rejected its first submission around seven months ago due to issues at a third-party manufacturer....
View ArticleFollowing a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot
Last week, Ovid Therapeutics disclosed layoff plans in an SEC filing following a Phase 3 flop for its Takeda-partnered epilepsy program. The news sent its stock price $OVID down 70%. Ovid has been here...
View ArticleYuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J: Yuhan licenses prostate cancer drug: The biotech will pay Seoul-based Ubix Therapeutics $3.6 million upfront and...
View Article